Creatine in Acidic RTDs: pH-Dependent Stability and Formulation Trade-Offs

Creatine monohydrate is highly stable as a dry crystalline powder, but it can convert to creatinine after it is dissolved. Lower pH and higher temperature generally accelerate this reaction, creating a development challenge for acidic ready-to-drink (RTD) beverages.

For brands and OEMs, adding creatine at the start of production is not enough. The finished beverage must retain the intended dose after processing, distribution and storage, while also meeting microbial, sensory and physical-stability requirements.

What the Solution-Stability Data Show

pH and Temperature Matter

In aqueous solution, creatine undergoes intramolecular cyclization to creatinine, which does not contribute to the intended creatine dose. Reviews report that after three days at 25°C, creatine degradation was approximately 4% at pH 5.5, 12% at pH 4.5 and 21% at pH 3.5. These figures illustrate the direction and possible scale of pH effects; they are not shelf-life predictions for every finished beverage.

First-order behaviour has been reported in pH 4.0 model systems, particularly during the earlier part of degradation. A commercial RTD may behave differently because its buffer system, water activity, ingredients and pH can change during storage.

A 45-Day Effervescent-Formulation Study

Ganguly and colleagues studied effervescent formulations containing di-creatine citrate. Creatine concentration declined by approximately 90% after 45 days at 25°C. Refrigerated samples showed a smaller decline but developed creatine monohydrate crystals from day 7. The solution pH also changed during room-temperature storage.

This study demonstrates that chemical conversion, solubility and crystallization can interact. However, it evaluated a specific effervescent formulation and should not be treated as a universal loss rate for creatine monohydrate RTDs.

The Main RTD Formulation Trade-Offs

Raising pH Changes the Preservation Strategy

A less acidic beverage may slow creatine conversion, but higher pH can reduce the effectiveness of acid-based preservation systems. Depending on the product, this may require aseptic processing, more intensive thermal treatment or another validated control strategy. Flavor, sweetness and acid balance may also need redevelopment.

Heat Exposure Must Be Measured, Not Assumed

Pasteurization, hot-fill and retort expose dissolved creatine to elevated temperatures, but actual loss depends on both temperature and residence time. A brief process step cannot be equated with months of warm storage. Development trials should measure creatine before processing, immediately after processing and during shelf life, while recording cooling, transport and retail-storage conditions.

Chemical Loss Is Not the Only Explanation

An apparent decline in creatine assay may reflect conversion to creatinine, crystallization, sedimentation or non-representative sampling. Developers should assess whether the intended dose dissolves at the processing temperature, whether crystals form after cooling, and whether electrolytes, sugars or acids change solubility. If the beverage is a suspension, redispersibility and sampling procedures must be defined.

What Should a Stability Program Measure?

A finished-product program should use a suitable method to quantify both creatine and creatinine. At minimum, the protocol should include:

• Creatine retained per serving and creatinine formation at release and planned shelf-life intervals.
• pH and pH drift, appearance, crystallization, sedimentation and redispersibility.
• Testing immediately before and after the intended thermal process.
• Real-time and justified accelerated conditions covering expected distribution temperatures.
• Microbial validation, sensory assessment and packaging-integrity checks.
• Representative sampling procedures for solutions and suspensions.

A raw-material CoA confirms the tested characteristics of the incoming creatine batch; it cannot establish the retained dose or shelf life of the finished RTD.

Evidence and Regulatory Boundaries

Most human efficacy studies use creatine powders, capsules or freshly prepared mixtures rather than long-shelf-life acidic RTDs. Performance claims should therefore be based on the amount of creatine actually delivered through the end of shelf life, not only the initial addition rate. Claim requirements also vary by market.

FDA GRAS Notice No. 931 includes an intended use for creatine monohydrate in energy drinks at 1.2 g per serving, equivalent to approximately 1.0 g creatine. It does not establish the stability of higher-dose acidic beverages, substantiate performance claims or determine compliance in other markets.

Patent literature also describes acidic creatine beverages formulated with electrolyte systems. A patent identifies a claimed technical approach; it is not independent confirmation that every commercial formulation will meet a stated shelf life.